JB‐9322, a new selective histamine H2‐receptor antagonist with potent gastric mucosal protective properties

• Published in: British journal of pharmacology 1995-05, Vol.115 (1), p.57-66
• Main Authors: Palacios, Beatriz, Montero, Ma Jose, Sevilla, Ma Angeles, Roman, Luis San
• Format: Article
• Language: English
• Subjects: Animals; Aspirin; Biological and medical sciences; cytoprotection; Digestive system; Ethanol; Gastric Acid - metabolism; gastric acid secretion; Gastric Mucosa - drug effects; Gastric Mucosa - metabolism; Guinea Pigs; Histamine H2 Antagonists - pharmacology; histamine H2‐receptor antagonist; In Vitro Techniques; Indomethacin; JB‐9322; Male; Medical sciences; mucosal protection; Muscarinic Antagonists; Pharmacology. Drug treatments; Piperidines - pharmacology; ranitidine; Ranitidine - pharmacology; Rats; Rats, Wistar; Stomach Diseases - chemically induced; Stomach Diseases - prevention & control
• ISSN: 0007-1188; 1476-5381
• DOI: 10.1111/j.1476-5381.1995.tb16319.x

1 JB‐9322 is a selective histamine H2‐receptor antagonist with gastric antisecretory activity and mucosal protective properties. 2 The affinity of JB‐9322 for the guinea‐pig atria histamine H2‐receptor was approximately 2 times greater than that of ranitidine. 3 In vivo, the ID50 value for the inhibition of gastric acid secretion in pylorus‐ligated rats was 5.28 mg kg−1 intraperitoneally. JB‐9322 also dose‐dependently inhibited gastric juice volume and pepsin secretion. In gastric lumen‐perfused rats, intravenous injection of JB‐9322 dose‐dependently reduced histamine‐, pentagastrin‐ and carbachol‐stimulated gastric acid secretion. 4 JB‐9322 showed antiulcer activity against aspirin and indomethacin‐induced gastric lesions and was more potent than ranitidine. 5 JB‐9322 effectively inhibited macroscopic gastric haemorrhagic lesions induced by ethanol. Intraperitoneal injection was effective in preventing the lesions as well as oral treatment. The oral ID50 value for these lesions was 1.33 mg kg−1. By contrast, ranitidine (50 mg kg−1) failed to reduce these lesions. In addition, the protective effect of JB‐9322 was independent of prostaglandin synthesis. 6 These results indicate that JB‐9322 is a new antiulcer drug that exerts a potent cytoprotective effect in addition to its gastric antisecretory activity.